Achieve Life Sciences

Achieve Life Sciences has licensed global rights to cytisine for smoking cessation and is obtaining marketing approval in US, EU, Japan (using a patented version) and in other markets using the currently marketed version.

​

Two Phase 3 trials have been completed in over 2,000 patients. Achieve expects to submit an MAA in Europe in late-2017. A third US Phase trial is scheduled for late-2017.